Find Clinical Trials | Cedars-Sinai

31 results found

Colon, Lung, Melanoma, Other Female Genital, Thyroid, Unknown Sites

KIN-2787 in Participants With BRAF and/or NRAS Mutation-Positive Solid Tumors

This early-phase clinical trial is designed for adults with advanced solid tumors that have spread (metastasized) and carry specific genetic mutations in the BRAF and/or NRAS genes—both of which are known to drive cancer progression. ...

Melanoma

PF-07799544 as a Single Agent and in Combination With Other Targeted Agents in BRAF-Mutant Melanoma and Other Solid Tumors

This study focuses on people who have melanoma (skin cancer) or other cancer with a specific change in the BRAF gene (BRAF alteration) and whose cancer has grown or spread. The study will explore the ...

Melanoma

Regeneron, R3767-ONC-2466, Ph2, open label, Melanoma, Fianlimab Plus Cemiplimab

Primary -Assess Overall Survival (OS) of patients with melanoma treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Secondary -Assess Progression-Free Survival (PFS) -Assess Objective Response Rate (ORR) -Assess Duration of Response (DOR) -Assess Disease Control Rate (DCR) ...

Melanoma, Unknown Sites

SWOG, S2101, PhII, open label, Cabozantinib + Nivolumab, Melanoma or HNSCC

Primary Objective: 1. To evaluate the feasibility of molecular characterization based on tumor mutation burden (TMB) for participant stratification, as assessed by the proportion of participants with less than or equal to a 21-day ...

Melanoma

Phase 2, Multi-Center, MSK, Melanoma

Primary objectives: 1. Determine best ORR by RECIST v1.1 separately among patients whose melanoma progressed on prior anti-PD-1 monotherapy (Cohort A) and on anti-PD-1 and anti-LAG-3 ICI therapy (Cohort B) Secondary objectives: 1. Assess safety of fianlimab, cemiplimab, ...